Opko Health

Discussion in 'Relypsa' started by anonymous, Mar 30, 2018 at 12:27 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    Co-promotion?
    Buyout?
    Increasing the size of the sales force before the AZ launch?
     

  2. anonymous

    anonymous Guest

    I have no idea what you’re talking about.
     
  3. anonymous

    anonymous Guest

    Opko Health - Renal division to co-promote Veltassa. They are already receiving IMS data for targeting.
     
  4. anonymous

    anonymous Guest

    Opko Health - Renal division to co-promote Veltassa. They are already receiving IMS data for targeting.
     
  5. anonymous

    anonymous Guest

    Not true.
     
  6. anonymous

    anonymous Guest

    Actually Opko is getting the data and the spin is that it's for market comparability (comparing crappy Rayaldee to your drug). Not kidding.
     
  7. anonymous

    anonymous Guest

     
  8. anonymous

    anonymous Guest

    Announcement after next week.
     
  9. anonymous

    anonymous Guest

    Definitely no co-promote. Vifor not happy with V sales. Thought cards would would use ALOT more. Most def do not want to pay bonuses to reps

    Vifor does NOT want to spend another penny no matter how necessary it might be to increase business and keep reps in 2019. No sales force expansion.

    Sales realignment is happening this year. Say they’re keeping same number of reps but tweaking.
     
  10. anonymous

    anonymous Guest

    I’m guessing that might be the reason for the mass exodus from Commercial. It’s easy to blame Vifor for not wanting to spend $$$, but have you taken a good look at Relypsa leadership? This is what happens when you get a bunch of rookies pretending to be leaders.